November 6, 2024 09:23 AM EST

At this year's ObesityWeek, GLP-1s aren’t the only talk of the town

Kyle LaHucik

Senior Reporter

SAN ANTONIO — As the GLP-1 class has taken over in recent years, a once-fringe conference has come into the spotlight for the biopharma industry. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

At this year's ObesityWeek, GLP-1s aren’t the only talk of the town

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

At this year's Obe­si­ty­Week, GLP-1s aren’t the on­ly talk of the town

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

At this year's ObesityWeek, GLP-1s aren’t the only talk of the town